 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Using Multiple Drugs in Combination Helps Patients with Advanced AIDS
3 July 2001 | Volume 135 Issue 1 | Page S19
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease." It is in the 3 July 2001 issue of Annals of Internal Medicine (volume 135, pages 17-26). The authors are EL Murphy, AC Collier, LA Kalish, SF Assmann, MF Para, TP Flanigan, PN Kumar, L Mintz, FR Wallach, and GJ Nemo, for the Viral Activation Transfusion Study Investigators.
What is the problem and what is known about it so far?
Since 1996, combination therapies with antiretroviral drugs have been shown to increase length of life in many people with AIDS. (Drugs that suppress HIV, the virus that causes AIDS, are called antiretroviral drugs.) Combination therapy usually consists of taking three or four drugs of different types at the same time. Each of these drugs works in a different way against HIV. Combination therapy for AIDS is commonly called highly active antiretroviral therapy, or HAART. Currently, patients with newly diagnosed AIDS routinely receive HAART. Although we know that HAART can extend life for many of these patients, we do not know whether or how much HAART helps patients with severe or advanced, late-stage AIDS.
Why did the researchers do this particular study?
To find out whether HAART lengthens life and decreases medical complications in patients with advanced AIDS.
Who was studied?
The study included 528 patients with advanced AIDS. All patients had severe anemia (low red blood cell counts) that required blood cell transfusions. Most were men (79%). One third of the patients were not taking any antiretroviral therapy when they entered the study, one quarter were already taking HAART, and the remainder were taking some antiretroviral therapies that are less intensive than HAART.
How was the study done?
The researchers recruited and followed patients from 1995 to 1999. During routine quarterly visits, the researchers asked patients whether and when their doctors had started them on HAART. The researchers also reviewed medical records and pathology reports to find out whether any patients died or experienced infections or other medical complications related to AIDS.
What did the researchers find?
Doctors more often prescribed HAART in the later years of the study than in the earlier years. For example, only 1% of the study patients had been given HAART as of January 1996, whereas 79% had been given it as of January 1999. During follow-up, 289 (55%) of the 528 patients died. Patients who took HAART lived longer and had fewer AIDS-related medical complications than patients who did not take HAART.
What were the limitations of the study?
The researchers had limited ability to determine exactly whether the patients took HAART as prescribed. Also, many factors may contribute to better outcomes in patients with AIDS, and some of these factors may be related to whether patients took HAART. Although the investigators took into account many of these factors, sorting out whether the improved outcomes are due to HAART or other factors is very difficult.
What are the implications of the study?
Highly active antiretroviral therapy appears to lengthen life and decrease complications related to AIDS, even in patients with advanced AIDS.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J.-J. Yoon, D. Chawla, T. Paal, M. Ndungu, Y. Du, S. Kurtkaya, A. Sun, J. P. Snyder, and R. K. Plemper High-Throughput Screening--Based Identification of Paramyxovirus Inhibitors J Biomol Screen, August 1, 2008; 13(7): 591 - 608. [Abstract] [PDF]
|
|
|
|
 |
|
 C M Wilcox and M S Saag Gastrointestinal complications of HIV infection: changing priorities in the HAART era Gut, June 1, 2008; 57(6): 861 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M Kitahata, B. Rodriguez, R. Haubrich, S. Boswell, W C. Mathews, M. M Lederman, W. B Lober, S. E V. Rompaey, H. M Crane, R. D Moore, et al. Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems Int. J. Epidemiol., February 8, 2008; (2008) dym231v1. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Rodriguez, H. Valdez, A. Mijch, K. Watson, M. M. Lederman, G. A. McComsey, C. V. Loupa, and I. Woolley Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART J Int Assoc Physicians AIDS Care (Chic Ill), September 1, 2007; 6(3): 198 - 202. [Abstract] [PDF]
|
|
|
|
 |
|
 L. K. White, J.-J. Yoon, J. K. Lee, A. Sun, Y. Du, H. Fu, J. P. Snyder, and R. K. Plemper Nonnucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2293 - 2303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Gilden, J. M. Kubisiak, and D. M. Gilden Managing Medicare's HIV Caseload in the Era of Suppressive Therapy Am J Public Health, June 1, 2007; 97(6): 1053 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Parsons, E. Rosof, and B. Mustanski Patient-related Factors Predicting HIV Medication Adherence among Men and Women with Alcohol Problems J Health Psychol, March 1, 2007; 12(2): 357 - 370. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Horberg, L. B. Hurley, D. B. Klein, S. E. Follansbee, C. Quesenberry, J. A. Flamm, G. M. Green, and T. Luu Surgical Outcomes in Human Immunodeficiency Virus-Infected Patients in the Era of Highly Active Antiretroviral Therapy Arch Surg, December 1, 2006; 141(12): 1238 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Bini, J. Park, and F. Francois Use of Flexible Sigmoidoscopy to Screen for Colorectal Cancer in HIV-Infected Patients 50 Years of Age and Older. Arch Intern Med, August 14, 2006; 166(15): 1626 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. R. Blanco, I. S. Garcia, J. G. Cerezo, J. M. P. S. de Rivera, P. M. Anaya, P. G. Raya, J. G. Garcia, J. R. A. Lopez, F. J. B. Hernandez, and J. J. V. Rodriguez Endothelial function in HIV-infected patients with low or mild cardiovascular risk J. Antimicrob. Chemother., July 1, 2006; 58(1): 133 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Gu, B. Allard, J. M. de Muys, J. Lippens, R. F. Rando, N. Nguyen-Ba, C. Ren, P. McKenna, D. L. Taylor, and R. C. Bethell In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection Antimicrob. Agents Chemother., February 1, 2006; 50(2): 625 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Khouli, A. Afrasiabi, M. Shibli, R. Hajal, C. R. Barrett, and P. Homel Outcome of Critically Ill Human Immunodeficiency Virus-Infected Patients in the Era of Highly Active Antiretroviral Therapy J Intensive Care Med, December 1, 2005; 20(6): 279 - 285. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Vlahov, N. Galai, M. Safaeian, S. Galea, G. D. Kirk, G. M. Lucas, and T. R. Sterling Effectiveness of Highly Active Antiretroviral Therapy among Injection Drug Users with Late-Stage Human Immunodeficiency Virus Infection Am. J. Epidemiol., June 1, 2005; 161(11): 999 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. R. Kitchen, S. Philpott, H. Burger, B. Weiser, K. Anastos, and M. A. Suchard Evolution of Human Immunodeficiency Virus Type 1 Coreceptor Usage during Antiretroviral Therapy: a Bayesian Approach J. Virol., October 15, 2004; 78(20): 11296 - 11302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Springer and A. Weinberg Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity J. Antimicrob. Chemother., September 1, 2004; 54(3): 582 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Eggers and P. L. Kimmel Is There an Epidemic of HIV Infection in the US ESRD Program? J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2477 - 2485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Narasimhan, A. J. Posner, V. A. DePalo, P. H. Mayo, and M. J. Rosen Intensive Care in Patients With HIV Infection in the Era of Highly Active Antiretroviral Therapy Chest, May 1, 2004; 125(5): 1800 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Furfine, C. T. Baker, M. R. Hale, D. J. Reynolds, J. A. Salisbury, A. D. Searle, S. D. Studenberg, D. Todd, R. D. Tung, and A. Spaltenstein Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir Antimicrob. Agents Chemother., March 1, 2004; 48(3): 791 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Koh, H. Nakata, K. Maeda, H. Ogata, G. Bilcer, T. Devasamudram, J. F. Kincaid, P. Boross, Y.-F. Wang, Y. Tie, et al. Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3123 - 3129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Roland, B. Lo, J. Braff, and P. G. Stock Key Clinical, Ethical, and Policy Issues in the Evaluation of the Safety and Effectiveness of Solid Organ Transplantation in HIV-Infected Patients Arch Intern Med, August 11, 2003; 163(15): 1773 - 1778. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lazzarin, B. Clotet, D. Cooper, J. Reynes, K. Arasteh, M. Nelson, C. Katlama, H.-J. Stellbrink, J.-F. Delfraissy, J. Lange, et al. Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia N. Engl. J. Med., May 29, 2003; 348(22): 2186 - 2195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Holzl, M. Stocher, V. Leb, H. Stekel, and J. Berg Entirely Automated Quantification of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in Plasma by Using the Ultrasensitive COBAS AMPLICOR HIV-1 Monitor Test and RNA Purification on the MagNA Pure LC Instrument J. Clin. Microbiol., March 1, 2003; 41(3): 1248 - 1251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Trevejo, J. G. Courtney, M. Starr, and D. J. Vugia Epidemiology of Salmonellosis in California, 1990-1999: Morbidity, Mortality, and Hospitalization Costs Am. J. Epidemiol., January 1, 2003; 157(1): 48 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Little, S. Holte, J.-P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, et al. Antiretroviral-Drug Resistance among Patients Recently Infected with HIV N. Engl. J. Med., August 8, 2002; 347(6): 385 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Beadle, C. Hartline, K. A. Aldern, N. Rodriguez, E. Harden, E. R. Kern, and K. Y. Hostetler Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir Exhibit Multiple-Log Enhancement of Antiviral Activity against Cytomegalovirus and Herpesvirus Replication In Vitro Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2381 - 2386. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
